May 22 |
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
|
May 20 |
Coya Therapeutics reports $5M strategic investment by ADDF
|
May 20 |
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
|
May 14 |
Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own 16%
|
May 10 |
Coya Therapeutics Reports First Quarter 2024 Financial Results
|
May 10 |
Coya Therapeutics GAAP EPS of -$0.35
|
May 9 |
Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results
|
May 1 |
Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseases
|
Apr 26 |
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
|
Apr 22 |
Coya Therapeutics to Participate in the Mizuho Neuroscience Summit
|